Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Equity /(Deficit)

v3.23.1
Consolidated Statement of Changes in Stockholders' Equity /(Deficit) - USD ($)
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common stock No Par Value [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 4,004 $ 43,411,487 $ (48,672,523) $ (5,257,032)
Balance, shares at Dec. 31, 2020   28,553,307      
Net loss (29,889,045) (29,889,045)
Exercise of prepaid equity forward contracts for Common Stock
Exercise of prepaid equity forward contracts for common stock, shares     466,716      
Reverse merger with Akers Biosciences Inc effective April 16, 2021 $ 144,524 42,332,834 42,477,358
Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares 72,992   8,335,627      
Issuance of post-merger MyMD Pharmaceutical Inc common shares at an exchange ratio of 0.7718 per pre-merger MyMD common share 43,415,491 $ (4,004) (43,411,487)
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement 15,036,051 15,036,051
Exercise of per-merger MyMD stock options
Exercise of per-merger MyMD stock options, shares     11,576      
Stock based compensation for services 90,002 90,002
Stock based compensation for services, shares     16,826      
Exercise of warrants for Common Stock 1,189,840 1,189,840
Exercise of warrants for common stock, shares     289,058      
Balance at Dec. 31, 2021 $ 144,524 102,064,218 (78,561,568) 23,647,174
Balance, shares at Dec. 31, 2021 72,992   37,673,110      
Net loss (15,197,336) (15,197,336)
Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500 5,550,028   5,550,028
Net proceeds from private placement of 1,411,764 common shares, net of offering costs of $449,500     1,411,764      
Exercise of prepaid equity forward contracts for Common Stock  
Exercise of prepaid equity forward contracts for common stock, shares     385,135      
Stock-based compensation – stock options 444,342   444,342
Stock-based compensation – restricted stock units 165,997   165,997
Stock-based compensation – warrants 84,851   $ 84,851
Exercise of per-merger MyMD stock options, shares          
Balance at Dec. 31, 2022 $ 144,524 $ 108,309,436 $ (93,758,904) $ 14,695,056
Balance, shares at Dec. 31, 2022 72,992   39,470,009